MountainView Hospital
November 03, 2021

MountainView Hospital and Sarah Cannon, the Cancer Institute of HCA Healthcare, announced today a collaboration for a new treatment option, blood and marrow transplant (BMT) services, to Nevada. Patients with blood cancer and blood disorders no longer have to leave the state for this specialized treatment option.

Patients with blood cancers such as leukemia, lymphoma or multiple myeloma may be recommended by their physician to undergo a blood and marrow transplant, which is sometimes referred to as a stem cell transplant or bone marrow transplant. Prior to this new program at MountainView Hospital, 100 percent of these patients had to leave the state to seek these services, which can be a barrier to receiving the most appropriate care. The first transplant at MountainView Hospital was performed this summer.

“We are pleased to fill a critical gap in Nevada’s cancer care infrastructure by bringing this needed service to our state,” said Julie Taylor, MountainView Hospital Chief Executive Officer. “We look forward to working with our community oncologists to keep their patients in Nevada for this specialized care.”

Per year, approximately 100 Nevada residents had to leave the state to obtain blood and marrow transplant care in another state which can create financial burdens and stressors to the patient and family/caregivers. In bringing this complex care to the Nevada community, cost and burden to patients can be reduced while providing the most cutting-edge services close to home.

Two transplant and cellular therapy veterans lead the program at MountainView Hospital - Dr. Delva Deauna-Limayo as the as BMT clinical program medical director and Dr. Shahram Mori as the transplant and cellular therapy clinical program medical director.

The Sarah Cannon Transplant and Cellular Therapy Program at MountainView Hospital is part of the Sarah Cannon Transplant and Cellular Therapy Network, offering patients convenient, community-based access to complex blood cancer care including acute leukemia, blood and marrow transplantation, clinical trials and innovative therapies. The Network performs approximately 1,200 blood and marrow transplants per year across its eight FACT/JACIE accredited programs in the United States and United Kingdom.

“Sarah Cannon is proud to bring state-of-the-art cancer close to home for those facing cancer. By partnering with MountainView Hospital, we are doing just that, bringing sophisticated offerings to patients in Nevada and the surrounding areas. Not only will blood cancer patients now have access to blood and marrow transplant services and a multidisciplinary care team, they will be able to do so with their support system of family and friends close by,” said Fred LeMaistre, MD, Senior Vice President, Sarah Cannon Market Operations and Physician-in-Chief of Blood Cancers.

MountainView in collaboration with Comprehensive Cancer Centers of Nevada physicians recognized the need for blood and marrow transplant services several years ago and designed its south tower oncology unit to include a dedicated blood and marrow transplant unit. The clinical team includes a comprehensive group of transplant professionals, including transplant physicians, transplant nurse coordinator, inpatient and outpatient transplant nurses, pharmacist, social workers, case managers and a registered dietitian.

During blood and marrow transplantation, blood-forming stem cells from bone marrow, umbilical cord blood or peripheral blood are infused into the patient to restore the body’s ability to produce blood and immune cells. Prior to the procedure, patients receive high doses of radiation and/or chemotherapy to treat the underlying disease and prepare for the transplant.

A patient’s own stem cells can be used during a transplant – a procedure known as an autologous transplant – or they can receive donor stem cells, known as an allogeneic transplant. Initially, the new Sarah Cannon Transplant & Cellular Therapy Program at MountainView Hospital will perform adult autologous transplants.

Patients and physicians who want to learn more about MountainView’s new program can call (702) 962-2106.